title: Two new 3' PML breakpoints in t(15;17)(q22;q21)-positive acute promyelocytic leukemia.
abstract: In the present article, two new types of PML/RARA junctions are described. Both were identified in diagnostic samples from two t(15;17)(q22;q21)-positive acute promyelocytic leukemia (APL) patients who failed to achieve complete remission. By using different sets of primers, reverse transcriptase polymerase chain reaction (RT-PCR) of PML/RARA junctions showed atypical larger bands compared with those generated from the three classical PML breakpoints already described. Sequence analysis of the fusion region of the amplified cDNAs allowed us to determine the specificity of these fragments in both patients. This analysis showed two new hybrid transcripts that were 53 and 306 base pairs (bp) longer than that expressed by the NB4 cell line (PML breakpoint within intron 6), and are the result of the direct joining of RARA exon 3 with PML exon 7a (patient 2) or the 5' portion of PML exon 7b (patient 1), respectively. In patient 1, RT-PCR analysis of the reciprocal RARA/PML junction showed a smaller transcript than that expected in bcr1 cases, while in patient 2 no amplified fragment was obtained. Cytogenetic analysis and/or fluorescence in situ hybridization (FISH) showed that both patients had the t(15;17) translocation. The clinical and hematological profiles expressed by the two patients carrying these unexpected types of PML/RARA rearrangement did not differ significantly from that commonly seen in other APLs with the exception of the poor outcome. Genes Chromosomes Cancer 27:35-43, 2000.
authors.affiliation: Hematology Service, Hospital Universitario de Salamanca and Centro de Investigacíon del Cancer (CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.
authors.forename: M C
authors.initials: MC
authors.lastname: Chillón
authors.forename: M
authors.initials: M
authors.lastname: González
authors.forename: R
authors.initials: R
authors.lastname: García-Sanz
authors.forename: A
authors.initials: A
authors.lastname: Balanzategui
authors.forename: D
authors.initials: D
authors.lastname: González
authors.forename: R
authors.initials: R
authors.lastname: López-Pérez
authors.forename: M V
authors.initials: MV
authors.lastname: Mateos
authors.forename: I
authors.initials: I
authors.lastname: Alaejos
authors.forename: C
authors.initials: C
authors.lastname: Rayón
authors.forename: J
authors.initials: J
authors.lastname: Arbeteta
authors.forename: J M
authors.initials: JM
authors.lastname: Hernández
authors.forename: A
authors.initials: A
authors.lastname: Orfao
authors.forename: J
authors.initials: J
authors.lastname: San Miguel
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001483:Base Sequence; D002884:Chromosomes, Human, Pair 15 / Q000235:genetics*; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics*; D003561:Cytarabine / Q000008:administration & dosage; D005091:Exons / Q000235:genetics; D017809:Fatal Outcome; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000235:genetics*; D008297:Male; D008969:Molecular Sequence Data; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014178:Translocation, Genetic / Q000235:genetics*; D014212:Tretinoin / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014212:Tretinoin; D015255:Idarubicin